Peer-reviewed veterinary case report
Treatment options for immune thrombocytopenia in dogs and cats
By LeVine, Dana N et al.·Published in Journal of veterinary internal medicine·2024·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats.
Plain-English summary
Managing immune thrombocytopenia (ITP), a condition where the immune system mistakenly attacks platelets in dogs and cats, is becoming more advanced, but there are currently no clear guidelines for veterinarians on how to treat it. The first line of treatment usually involves high doses of glucocorticoids, a type of steroid, but there is still uncertainty about what other treatments might work best. Options for additional treatment include other immunosuppressive medications, and in more severe cases, treatments like transfusions or even surgery to remove the spleen may be considered. A group of experts reviewed a large amount of research to create recommendations for treating ITP, but they found that more studies are needed to improve understanding and treatment options. Overall, while there is progress in managing ITP, the treatment landscape is still evolving and requires further research.
Abstract
Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell-containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38779941/